Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.
Publication/Presentation Date
7-21-2020
Abstract
Rabies is nearly 100% lethal in the absence of treatment, killing an estimated 59,000 people annually. Vaccines and biologics are highly efficacious when administered properly. Sixteen rabies-related viruses (lyssaviruses) are similarly lethal, but some are divergent enough to evade protection from current vaccines and biologics, which are based only on the classical rabies virus (RABV). Here we present the development and characterization of LyssaVax, a vaccine featuring a structurally designed, functional chimeric glycoprotein (G) containing immunologically important domains from both RABV G and the highly divergent Mokola virus (MOKV) G. LyssaVax elicits high titers of antibodies specific to both RABV and MOKV Gs in mice. Immune sera also neutralize a range of wild-type lyssaviruses across the major phylogroups. LyssaVax-immunized mice are protected against challenge with recombinant RABV and MOKV. Altogether, LyssaVax demonstrates the utility of structural modeling in vaccine design and constitutes a broadened lyssavirus vaccine candidate.
Volume
32
Issue
3
First Page
107920
Last Page
107920
ISSN
2211-1247
Published In/Presented At
Fisher, C. R., Lowe, D. E., Smith, T. G., Yang, Y., Hutson, C. L., Wirblich, C., Cingolani, G., & Schnell, M. J. (2020). Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups. Cell reports, 32(3), 107920. https://doi.org/10.1016/j.celrep.2020.107920
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
32697993
Department(s)
Administration and Leadership
Document Type
Article